A Question of Class
Dapagliflozin FDA Rejection Not End of SGLT2 Inhibitors
The FDA's decision to reject AstraZeneca plc and Bristol-Myers Squibb Co.'s Type II diabetes drug dapagliflozin last week was no surprise, given the drug's spotty safety record and a negative advisory panel vote. But the rejection isn't necessarily a death sentence for dapagliflozin, or for other SGLT2 inhibitors in development.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription

